Virtual Library
Start Your Search
L. Chen
Author of
-
+
P1.03 - Chemotherapy/Targeted Therapy (ID 689)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Chemotherapy/Targeted Therapy
- Presentations: 1
- Moderators:
- Coordinates: 10/16/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P1.03-032 - Observation of Durative Infusion Endostar Combined with Chemotherapy Within Vascular Normalization Period in Advanced NSCLC (ID 9242)
09:30 - 09:30 | Author(s): L. Chen
- Abstract
Background:
To investigate the safety and efficacy of recombinant human endostatin (endostar) administrated by durative infusion combined with chemotherapy within the vascular normalization period in treating advanced non‐small cell lung cancer (NSCLC).
Method:
From February 2012 to December 2013, 34 cases of IIIB‐IV NSCLC patients were treated with endostar (15mg/m2) durative infusion combined with chemotherapy within vascular normalization time. Endostar was durative infusion every 24 hour for 7 days, and in the fourth day of the normalization time patients were received combined chemotherapy based on platinum, 21 days per cycle. All patients received 2‐6 cycles; efficacy was evaluated every two cycles, and side effects were recorded every cycle.
Result:
Every patient was received at least 2 cycles, one patient achieved CR, 14 patients were PR and 8 patients were SD. Eleven patients were PD. The overall response rate (ORR) of 34 patients was 44.1%, and non‐squamous NSCLC was 38.9%, squamous NSCLC was 50.0%. First‐line treatment of patient showed higher ORR, 53.9%. Major toxicities related to endostar were sinus tachycardia in one case, and one case hypertension. No serious side effects such as bleeding were observed.
Conclusion:
Endostar (15mg/m2) durative infusion combined with normalization period chemotherapy for NSCLC was an efficacy and safe regimen. A larger prospective randomized controlled clinical study is worth to carry out in future.
